The short answer
It is not established that Panax ginseng changes linagliptin absorption or clinical effectiveness. Have the pharmacist review the product; enzyme findings from other test drugs do not provide an exact dose adjustment.
What this answer covers
Asian ginseng root preparations; other species and extracts differ.
- Supplement or preparation
- Panax ginseng
- Medication ingredient
- linagliptin
What was actually measured
One healthy-volunteer study found lower midazolam exposure after Panax ginseng, while fexofenadine exposure was unchanged. An older-adult study using a different testing method did not find the same CYP3A4 signal. Neither measured linagliptin.
How the medicine label applies
Linagliptin’s label warns that strong P-gp or CYP3A4 inducers can lower its exposure. These ginseng studies do not establish that the tested product, or your product, has that strength of effect on linagliptin.
Bring the complete product label
Record the species or ingredient, extract strength, daily amount and start date. Report glucose changes so the clinician can assess supplement effects alongside meals and other medicines.
Keep the prescribed medicine plan
Continue the prescribed linagliptin dose and review the complete medicine and supplement list with the pharmacist. A new supplement is not a reason to adjust this medicine yourself or invent a separation interval.
Evidence and practical considerations
Absorption & effectiveness
Original absorption/effectiveness claim remains insufficient: human probe findings require an untested medication-specific bridge.
- Exact scope
- Asian ginseng root preparations; other species and extracts differ. with Exact linagliptin single-ingredient oral tablets. Exact RxNorm IN1100699 linagliptin; single-ingredient oral tablets. Combination medicines are not assumed equivalent.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No direct exact-pair human pharmacokinetic or clinical-effect study identified; no safe dose or protective spacing established.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline glucose and nutrient status.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed linagliptin.
Glucose-dependent DPP4 action; increased hypoglycemia with insulin/secretagogues. Strong P-gp/CYP3A4 inducers reduce exposure; CYP3A4 inhibition does not automatically imply a clinically relevant change.
How this applies: Exact RxNorm IN1100699 linagliptin; single-ingredient oral tablets. Combination medicines are not assumed equivalent.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Twelve healthy volunteers.
Midazolam AUC fell about 34%; fexofenadine pharmacokinetics were unchanged.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Probe study, not linagliptin; reduced midazolam exposure does not establish strong P-gp/CYP3A4 induction by every ginseng product.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Twelve healthy adults aged 60 to 76 years.
Panax ginseng produced a small CYP2D6 effect, without the CYP3A4 induction reported for St John’s wort in this study.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Single-timepoint ratio differs from full concentration-time measurements; no linagliptin or clinical efficacy endpoint.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: 1c9ac1e79bc72a0d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.